Controlled Release of Nor-β-lapachone by PLGA Microparticles: A Strategy for Improving Cytotoxicity Against Prostate Cancer Cells

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2016 Jul 8

PMID 27384551

Citations 7

Authors

Marcilia P Costa

Anderson C S Feitosa

Fatima C E Oliveira

Bruno C Cavalcanti

Eufranio N da Silva

Gleiston G Dias

Francisco A M Sales

Bruno L Sousa

Ito L Barroso-Neto

Claudia Pessoa

Ewerton W S Caetano

Stefano Di Fiore

Rainer Fischer

Luiz O Ladeira

Valder N Freire

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is one of the most common malignant tumors in males and it has become a major worldwide public health problem. This study characterizes the encapsulation of Nor-β-lapachone (NβL) in poly(d,l-lactide-co-glycolide) (PLGA) microcapsules and evaluates the cytotoxicity of the resulting drug-loaded system against metastatic prostate cancer cells. The microcapsules presented appropriate morphological features and the presence of drug molecules in the microcapsules was confirmed by different methods. Spherical microcapsules with a size range of 1.03 ± 0.46 μm were produced with an encapsulation efficiency of approximately 19%. Classical molecular dynamics calculations provided an estimate of the typical adsorption energies of NβL on PLGA. Finally, the cytotoxic activity of NβL against PC3M human prostate cancer cells was demonstrated to be significantly enhanced when delivered by PLGA microcapsules in comparison with the free drug.

Citing Articles

Nanofunctionalized Microparticles for Glucose Delivery in Three-Dimensional Cell Assemblies.

Fois M, Zengin A, Song K, Giselbrecht S, Habibovic P, Truckenmuller R ACS Appl Mater Interfaces. 2024; 16(14):17347-17360.

PMID: 38561903 PMC: 11009907. DOI: 10.1021/acsami.4c02321.

In vitro anti-inflammatory activity and ameliorative effects on gastric ulcers of Licania rigida benth seed extract.

de Freitas Rocha J, de Castro Viana L, Filho L, de Almeida T, Neto J, Neto V Inflammopharmacology. 2023; 31(5):2631-2640.

PMID: 37420144 DOI: 10.1007/s10787-023-01283-0.

Investigating PLGA microparticle swelling behavior reveals an interplay of expansive intermolecular forces.

Rapier C, Shea K, Lee A Sci Rep. 2021; 11(1):14512.

PMID: 34267274 PMC: 8282844. DOI: 10.1038/s41598-021-93785-6.

The Effect of Fluid Shear Stress on the In Vitro Release Kinetics of Sirolimus from PLGA Films.

Zheng Q, Chu Z, Li X, Kang H, Yang X, Fan Y Polymers (Basel). 2019; 9(11).

PMID: 30965925 PMC: 6418679. DOI: 10.3390/polym9110618.

NQO1 is Required for β-Lapachone-Mediated Downregulation of Breast-Cancer Stem-Cell Activity.

Kim D, Cho J Int J Mol Sci. 2018; 19(12).

PMID: 30513573 PMC: 6321092. DOI: 10.3390/ijms19123813.

References

Li C, Li Y, Pinto A, Pardee A . Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci U S A. 1999; 96(23):13369-74. PMC: 23954. DOI: 10.1073/pnas.96.23.13369. View

Bolton J, Trush M, Penning T, Dryhurst G, Monks T . Role of quinones in toxicology. Chem Res Toxicol. 2000; 13(3):135-60. DOI: 10.1021/tx9902082. View

Bertram J . The molecular biology of cancer. Mol Aspects Med. 2001; 21(6):167-223. DOI: 10.1016/s0098-2997(00)00007-8. View

Lin R, Shi Ng L, Wang C . In vitro study of anticancer drug doxorubicin in PLGA-based microparticles. Biomaterials. 2005; 26(21):4476-85. DOI: 10.1016/j.biomaterials.2004.11.014. View

Perez-Sacau E, Diaz-Penate R, Estevez-Braun A, Ravelo A, Garcia-Castellano J, Pardo L . Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line. J Med Chem. 2007; 50(4):696-706. DOI: 10.1021/jm060849b. View

Blanco E, Bey E, Dong Y, Weinberg B, Sutton D, Boothman D . Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release. 2007; 122(3):365-74. PMC: 2064869. DOI: 10.1016/j.jconrel.2007.04.014. View

Lobo N, Shimono Y, Qian D, Clarke M . The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007; 23:675-99. DOI: 10.1146/annurev.cellbio.22.010305.104154. View

da Silva Junior E, de Souza M, Pinto A, Pinto M, Goulart M, Barros F . Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone. Bioorg Med Chem. 2007; 15(22):7035-41. DOI: 10.1016/j.bmc.2007.07.043. View

Mundargi R, Babu V, Rangaswamy V, Patel P, Aminabhavi T . Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release. 2007; 125(3):193-209. DOI: 10.1016/j.jconrel.2007.09.013. View

10.

DeBerardinis R, Lum J, Hatzivassiliou G, Thompson C . The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7(1):11-20. DOI: 10.1016/j.cmet.2007.10.002. View

11.

FIESER L, FIESER M . Naphthoquinone antimalarials; the Hooker oxidation reaction. J Am Chem Soc. 1948; 70(10):3215-22. DOI: 10.1021/ja01190a005. View

12.

Santos S, Santana J, Maia Jr F, Lemos V, Freire V, Caetano E . Adsorption of ascorbic acid on the C60 fullerene. J Phys Chem B. 2008; 112(45):14267-72. DOI: 10.1021/jp8048263. View

13.

Wei P, Zhang X, Tu S, Yan S, Ying H, Ouyang P . New potential inhibitors of DNA topoisomerase. Part II: Design and synthesis of alpha-lapachone derivatives under microwave irradiation. Bioorg Med Chem Lett. 2008; 19(3):828-30. DOI: 10.1016/j.bmcl.2008.12.006. View

14.

de Almeida E, Lucena F, Silva C, da Silva Costa-Junior W, Cavalcanti J, Couto G . Toxicological assessment of beta-lapachone on organs from pregnant and non-pregnant rats. Phytother Res. 2009; 23(9):1276-80. DOI: 10.1002/ptr.2646. View

15.

Abate-Shen C, Shen M . Diagnostics: The prostate-cancer metabolome. Nature. 2009; 457(7231):799-800. DOI: 10.1038/457799a. View

16.

Salustiano E, Netto C, Fernandes R, da Silva A, Bacelar T, Castro C . Comparison of the cytotoxic effect of lapachol, alpha-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells. Invest New Drugs. 2009; 28(2):139-44. DOI: 10.1007/s10637-009-9231-y. View

17.

Fattal E, Barratt G . Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br J Pharmacol. 2009; 157(2):179-94. PMC: 2697810. DOI: 10.1111/j.1476-5381.2009.00148.x. View

18.

Vis A, Schroder F . Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 2009; 104(4):438-48. DOI: 10.1111/j.1464-410X.2009.08695.x. View

19.

Jeong S, Park S, Yoon S, Jung J, Woo H, Yi S . Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization. J Control Release. 2009; 139(3):239-45. DOI: 10.1016/j.jconrel.2009.07.007. View

20.

Acharya G, Shin C, McDermott M, Mishra H, Park H, Kwon I . The hydrogel template method for fabrication of homogeneous nano/microparticles. J Control Release. 2009; 141(3):314-9. DOI: 10.1016/j.jconrel.2009.09.032. View